Fact CheckerSign in

NCT07514819Recruiting

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

Source: ClinicalTrials.gov · Last updated 21 Aug 2026

Brief summary (registry, in English)

Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as needed. Participants will receive weekly or every-other-week CT scans, with MRI when appropriate, to assess whether the original plan remains accurate. Treatment plans will be updated if tumor coverage decreases by more than 5% or if radiation dose to normal tissues increases by more than 10%; otherwise, the original plan will continue. The study aims to determine how often plan adjustments are needed and to identify which disease sites are most likely to experience significant anatomical changes during treatment. Primary Objective: * Define the frequency of replanning necessary to ensure tumor coverage never falls below 95% (or 5% drop) of the prescribed daily dose in participants with intact (gross) tumors to keep the tumor control optimal throughout the multi-week treatment regimen. * Define the frequency of replanning necessary to ensure organs-at-risk (critical organs) do not deviate by more than 10% of the initially approved dose constraints to keep the normal tissue complication minimal throughout the multi-week treatment regimen. Secondary Objectives * Establish a cone beam CT (CBCT)-based framework for quantifying body surface changes throughout the treatment course. This goal will be achieved by developing a novel algorithm that detects and tracks external anatomical variations longitudinally, without requiring CBCT image enhancement, enabling precise assessment of daily participant setup consistency and anatomical stability. * Overcome daily CBCT quality limitations by generating synthetic CT images that accurately represent daily anatomy and support proton dose recalculation or verification planning. This goal will be achieved by developing a hybrid pipeline that integrates deep learning models with the deformable image registration algorithm, trained and validated on disease site-specific data. This will enable precise dose mapping and tissue density estimation, directly supporting adaptive planning decisions without the need of diagnostic- quality CT images.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
100 (estimated)
First submitted
31 Mar 2026
Start date
20 Aug 2026
Primary completion date
31 Aug 2029
Lead sponsor
St. Jude Children's Research Hospital
NCT number
NCT07514819

What you commit to

  • Study type: Interventional
  • Planned participants: 100
  • From 20 Aug 2026 to the primary completion date, 31 Aug 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participants who do not undergo proton therapy.
  • Participants who are prescribed equal or less than 5 fractions of proton therapy.

Other illness

  • Participants with severe comorbid conditions that may impact imaging feasibility.

Lab values

  • Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \>10 years of age or post-menarchal must have a negative serum or urine pregnancy test
    • All participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.

Other

  • Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.
  • Participants who are diagnosed with Wilm's tumor or neuroblastoma
  • Inability to obtain written consent from research participant or legal guardian/representative.

Who the study is looking for

  • Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.
  • Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.
  • Research participant or legal guardian/representative gives written informed consent.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
St. Jude Children's Research Hospital
Coordinator of this site? Confirm its status
MemphisUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.